Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | AKT1 | P31749 | 2/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | GLS | O94925 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30632213 | 1.00 | AURKA (0.49) | AURKARPS6KB1AKT1SIRT2HDAC3 | |
| SCHEMBL13735759 | 0.89 | CYP3A4 (0.49) | AURKARPS6KB1AKT1SIRT2HDAC3 | |
| SCHEMBL1858721 | 0.87 | PDK1 (0.58) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL29991279 | 0.87 | MAPT (0.54) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL1985668 | 0.87 | MAPT (0.54) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL31139332 | 0.87 | PDK1 (0.58) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL8711740 | 0.87 | AURKA (0.50) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL7911540 | 0.85 | AURKA (0.49) | AURKARPS6KB1SIRT2HDAC3HDAC1 | |
| SCHEMBL16246277 | 0.85 | AURKA (0.49) | AURKARPS6KB1AKT1SIRT2HDAC3 | |
| SCHEMBL29969056 | 0.85 | AURKA (0.52) | AURKARPS6KB1SIRT2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117568743-B | Surface corrosion-resistant wear-resistant treatment process for iron-based material | 江苏普坦科金属科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-117568743-A | Surface corrosion-resistant wear-resistant treatment process for iron-based material | 江苏普坦科金属科技有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-20260125417-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | LILLY CO ELI (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250345441-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-11-13 | — | — | US | disclosed |
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) | 2025-10-23 | — | — | US | disclosed |
| US-20250276067-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-09-04 | — | — | US | disclosed |
| US-12404298-B2 | Glucocorticoid receptor agonists | ELI LILLY AND COMPANY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4590686-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | Eli Lilly and Company (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4558511-A2 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | Firefly Bio, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-6680311-B1 | ANTICARCINOGENIC, ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | ELI LILLY AND COMPANY | 2004-01-20 | — | — | US | disclosed |
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-01-30 | — | — | US | disclosed |
| US-6458952-B1 | ENZYME INHIBITORS FOR SERINE METHODS FOR PREVENTING AND TREATING THROMBOTIC CONDITIONS SUCH AS CORONARY ARTERY AND CEREBROVASCULAR DISEASE WITH COMPOUNDS THAT INHIBIT SERINE PROTEASES OF THE COAGULATION CASCADE. | PHARMACIA CORPORATION | 2002-10-01 | — | — | US | disclosed |
| EP-1178971-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | Pharmacia Corporation (US) | 2002-02-13 | — | — | EP | disclosed |
| WO-2001087852-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2001-11-22 | — | — | WO | disclosed |
| US-6191273-B1 | 3,6,10,14-SUBSTITUTED-3,6,10,16-TETRAAZABICYCLO(10.3.1)-HEXADE CA-1(16),12,14-TRIENE COMPOUNDS OF GIVEN FORMULA; ANTIBACTERIAL AND OTHER UTILITIES, SUCH AS TO SCREEN FOR PESTICIDES OR DRUGS | ISIS PHARMACEUTICALS, INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000069833-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS AS ANTICOAGULATIVE AGENTS | PHARMACIA CORPORATION (US) | 2000-11-23 | — | — | WO | disclosed |
| CN-1233957-A | Pharmaceutical compositions | LILLY CO ELI (US) | 1999-11-03 | — | — | CN | disclosed |
| WO-1999011612-A2 | SUBSTITUTED CYCLIC COMPOUNDS AND MIXTURES COMPRISING SAME | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030023086-A1 | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade | TFPI, PLAT, PLAU | AURKA 1910/4885RPS6KB1 1625/4885AKT1 2727/4885 |
| US-20250345441-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | MTHFD1, DHFR, ABCG2 | AURKA 56/4885RPS6KB1 2431/4885AKT1 1831/4885 |
| US-12404298-B2 | Glucocorticoid receptor agonists | NR3C1, NR3C2, MC2R | AURKA 2822/4885RPS6KB1 2520/4885AKT1 1222/4885 |
| US-20250276067-A1 | ANTICANCER DRUGS AND METHODS OF MAKING AND USING SAME | MTHFD1, DHFR, ABCG2 | AURKA 56/4885RPS6KB1 2431/4885AKT1 1831/4885 |
| US-20250353874-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | AURKA 2822/4885RPS6KB1 2520/4885AKT1 1222/4885 |
| US-20260125417-A1 | GLUCOCORTICOID RECEPTOR AGONISTS | NR3C1, NR3C2, MC2R | AURKA 4047/4885RPS6KB1 2032/4885AKT1 1021/4885 |
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | AURKA 289/4885RPS6KB1 1026/4885AKT1 400/4885 |
| US-20250325687-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR7, TLR8 | AURKA 3017/4885RPS6KB1 1449/4885AKT1 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.